Pioneers in the treatment of
chronic kidney disease


ProKidney is an advanced biotech company built by innovators who are developing pioneering therapies that will transform the medical landscape and change patients’ lives.

Our technology regenerates diseased kidneys using a patient’s own cells and may prevent or delay dialysis or transplant.

We aspire to cure kidney disease, not manage kidney failure.

Recent Events

Research Article – Advances in CKD 2021

Advanced cell therapies with autologous, homologous cells show promise to affect reparative and restorative changes in the chronic kidney disease (CKD) nephron. We present our protocol and preliminary analysis of an IRB-approved, phase I single-group, open-label trial that tests the safety and efficacy of Renal Autologous Cell Therapy (REACT; NCT 04115345) in adults with congenital anomalies of the kidney and urinary tract (CAKUT).


ProKidney’s technology has the potential to restore kidney function by using the patient’s own (autologous) kidney cells.


We have a range of approaches that can help tackle the challenges you might face in the development of cell and gene therapies.


Providing the highest quality of cGMP cell therapy manufacturing and related services

Clinical Trials

ProKidney is currently conducting multiple Phase 2 clinical trials for its REACT product.